Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

Latest Articles

  • AML3D announces stronger FY26, with positive EBITDA reported in the second half
    AML3D announces stronger FY26, with positive EBITDA reported in the second half
    • News

  • Refurbished tech gives Harris Technology a second life
    Refurbished tech gives Harris Technology a second life
    • News

  • Imagion Biosystems Advances MagSense® Phase 2 Trial
    Imagion Biosystems Advances MagSense® Phase 2 Trial
    • News

  • Acrux-developed Menopause Hormone Therapy to enter Australian market
    Acrux-developed Menopause Hormone Therapy to enter Australian market
    • News

  • Evion Expands Critical Minerals Push with Nevada Fluorspar Option
    Evion Expands Critical Minerals Push with Nevada Fluorspar Option
    • News

  • Green360 Secures Holcim as First Commercial Eco-Clay Customer in Major Validation Milestone
    Green360 Secures Holcim as First Commercial Eco-Clay Customer in Major Validation Milestone
    • News

  • Aerometrex Expands MetroMap Partner Program as Scalable Model Gains Traction
    Aerometrex Expands MetroMap Partner Program as Scalable Model Gains Traction
    • News

  • Middle East Conflict Starts to Hurt Corporate Earnings Outlooks
    Middle East Conflict Starts to Hurt Corporate Earnings Outlooks
    • News

  • European Lithium and Critical Metals Secure Control of Tanbreez Rare Earth Project
    European Lithium and Critical Metals Secure Control of Tanbreez Rare Earth Project
    • News

  • Harris Technology’s refurbished boom signals FY26 profit inflection
    Harris Technology’s refurbished boom signals FY26 profit inflection
    • News

BRE Wins Final Permit to Advance Rare Earth Pilot Plant in Brazil

  • In News
  • September 4, 2025
  • Tim Grey
BRE Wins Final Permit to Advance Rare Earth Pilot Plant in Brazil

Brazilian Rare Earths Limited (ASX:BRE) has cleared its last regulatory hurdle to begin pilot operations at its rare earth beneficiation and hydrometallurgy plant within the Camaçari Petrochemical Complex located in Bahia, Brazil, with operations expected to commence in mid-2026.

The company says this marks a decisive step in moving from discovery to development in a market where demand for rare earth elements continues to grow.

“Selecting Camaçari was a deliberate choice. Brazil’s largest petrochemical and industrial complex brings coordinated permitting, world-class infrastructure and a skilled workforce, all of which shorten timelines and lower risk,” said BRE Managing Director and CEO, Bernardo da Veiga.

Secure Permit Strengthens Rare Earth Push

Brazil’s National Authority on Nuclear Safety (ANSN) has issued BRE with final operating authorisation for its pilot plant and laboratory facility inside the Camaçari Petrochemical Complex, a site about 260 kilometres northeast of the company’s Monte Alto Project.

The approval is significant, as ANSN regulates nuclear-related components to the highest safety standards. Without this authorisation, pilot operations would not have been possible.

“This Federal authorisation highlights our strong government engagement and confirms we can operate to the highest safety standards as we move decisively from rare earth discovery to development,” said Mr da Veiga.

Pilot Plant to Define Pathways

The pilot facility will focus on optimising beneficiation and hydrometallurgy pathways for BRE’s high-grade and ultra-high-grade rare earth mineralisation. It will also confirm key technical parameters and support the company’s downstream separation process work.

In practical terms, this means the plant is a crucial testing ground before moving toward potential large-scale commercial production.

Location Brings Industrial Advantages

BRE highlights that Camaçari is more than just a location – it is Brazil’s largest petrochemical and industrial complex. This setting provides several operational benefits:

  • Regulatory certainty through mature oversight of advanced chemical and metallurgical businesses
  • Streamlined permitting processes across Federal and State agencies
  • World-class infrastructure, including utilities, transport links, and power
  • Cost efficiencies with nearby suppliers of reagents and chemicals
  • Skilled workforce experienced in industrial operations

The combination of infrastructure and cost advantages is expected to enhance BRE’s competitiveness when scaling up.

Looking Ahead

The pilot plant is expected to begin operations in mid-2026, marking a key milestone for BRE’s long-term rare earths strategy. With growing demand for rare earths in clean energy, defence, and high-tech applications, the company is positioning itself to play a larger role in the supply chain.

As Mr da Veiga noted, the decision to locate at Camaçari reflects BRE’s emphasis on shortening timelines and lowering development risk while maintaining the highest safety standards.

  • About
  • Latest Posts
Tim Grey
Latest posts by Tim Grey (see all)
  • AML3D announces stronger FY26, with positive EBITDA reported in the second half - September 1, 2026
  • Imagion Biosystems Advances MagSense® Phase 2 Trial - August 27, 2026
  • Acrux-developed Menopause Hormone Therapy to enter Australian market - May 28, 2026
  •  
  •  
  •  
  •  
  • BRE
  • News

Leave a Comment

You must be logged in to post a comment.

  • About
  • Latest Posts
Tim Grey
Latest posts by Tim Grey (see all)
  • AML3D announces stronger FY26, with positive EBITDA reported in the second half - September 1, 2026
  • Imagion Biosystems Advances MagSense® Phase 2 Trial - August 27, 2026
  • Acrux-developed Menopause Hormone Therapy to enter Australian market - May 28, 2026

Login or register for free to access unlimited reading

Register Now!
  • About
  • Latest Posts
Tim Grey
Latest posts by Tim Grey (see all)
  • AML3D announces stronger FY26, with positive EBITDA reported in the second half - September 1, 2026
  • Imagion Biosystems Advances MagSense® Phase 2 Trial - August 27, 2026
  • Acrux-developed Menopause Hormone Therapy to enter Australian market - May 28, 2026
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.